About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease

NCT06810960·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Eisai Korea Inc. Medical department Serena SoYoun Kwon
CONTACT
+82-2-3451-5533 s-kwon@eisaikorea.com

Lead

Eisai Korea Inc.

Age

19–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Enrolled in JOY-ALZ before the decision to treat with LEQEMBI
The clinical decision to treat with LEQEMBI has already been made
Provides written informed consent for the use of medical information to be shared with Eisai Korea Inc.

You may not be if

Currently participating in an interventional clinical study

The record

StatusRecruiting

PhaseNo phase

Taking part3,000

StartedFeb 2025

UpdatedApr 21, 2026

Conditions

Alzheimer's Disease

Where1

Eisai Trial Site #1
Nutley, New Jersey, United States